Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Peripheral Neuropathy With Type 2 Diabet...
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to investigate whether sensory stimulations from a neuroprosthesis device (Walkasins®) can increase physical activity and improve gait quality in persons with peripheral neuropathy (PN). The main question it aims to answer is whether Walkasins enhances habitual activity patterns in adults with peripheral neuropathy. Participants will do the following as part of the study: * Complete a sensation and balance assessment to determine eligibility for the study. * Answer questions about their medical history, physical function, balance confidence, and sleep. * Perform various balance and walking tasks on three separate occasions. One of the tests involves walking for six minutes without a cane or walker. * Wear an activPAL activity monitor for ten days on three separate occasions and return it to the researcher as directed. * Wear Walkasins for ten weeks as part of their daily routine. Walkasins consists of two parts: 1) an insole that fits inside the shoe and 2) a strap that secures around the ankle.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: External, lower limb sensory prosthesis — Walkasins is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

Primary Outcomes

  • Activity Score--Metabolic Equivalents (METs) (Over a period of ~12 weeks)
  • Step Count (Over a period of ~12 weeks)
  • Total Sedentary Time (Over a period of ~12 weeks)
  • 6-Minute Walk Test--Phase Coordination Index (PCI) (Baseline, Walkasins Initiation, Follow-up (Week 10))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-25
Completion: 2027-12
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RxFunction Inc.
Collaborators: Brooks Rehabilitation
Principal Investigators:
  • Sutton B Richmond, PhD (STUDY_DIRECTOR) - RxFunction Inc.
Contact Information
Study Contact:
Dorian Rose, PT, MS, PhD, FAPTA
352-273-8307
research@rxfunction.com
Hannah Grimes
904-528-3159
Hannah.Grimes@brooksrehab.org
Mark B Bowden, PhD
904.345.6626
research@rxfunction.com
Brooks Rehabilitation Center
Interventions
  • Device: External, lower limb sensory prosthesis — Walkasins is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
Study Locations (1 sites)
Brooks Rehabilitation Center, Jacksonville, Florida 32216 United States
Eligibility Criteria
Inclusion Criteria: * Be 60 years of age or older * Have a diagnosis of PN with plantar sensory loss * Demonstrate balance impairment, defined as a Single-Leg Stance time of \<23 seconds * Be able to walk independently for at least 6 minutes without the use of an assistive device (rest breaks permitted) * Be willing to use the Walkasins device as recommended * Be willing to participate in all aspects of physical activity monitoring and study assessments Exclusion Criteria: * Under 60 years old * Do not have a diagnosis of PN with plantar sensory loss * Self-reported acute thrombophlebitis, including deep vein thrombosis * Self-reported severe peripheral vascular disease * Untreated lymphedema * Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use * Self-reported, untreated fractures in the foot and ankle * Other neurological or musculoskeletal conditions that moderately or severely impact walking * Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins * Weight of more than 300 pounds * Inability to perceive vibration from Walkasins Haptic Module * Do not demonstrate balance impairments, defined as a Single-Leg Stance time of \<23 seconds
Conditions Type 1 Diabetes
Phase Not Applicable
Enrollment 550
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab and the experience of participants with stage 2 type 1 diabetes who have not been infused with teplizumab, and to compare descriptively the experiences of the two groups. Primary Objective: \- To characterize health related quality of life, diabetes-related anxiety, diabetes-related burden, and ease of diabetes management, and how participants feel, form and function in those who infused and those who did not infuse with teplizumab Secondary Objectives: * To show the clinical transitions experienced by those who infused and those who did not infuse with teplizumab * To describe the prevalence and timing of diabetes misclassification and the temporal patterns between misclassification, antibody testing, and the correct diagnosis of type 1 diabetes in those who infused and those who did not infuse with teplizumab * To estimate the impact of diagnostic misclassification on the timing of progression to stage 3 type 1 diabetes in those who infused and those who did not infuse with teplizumab * To characterize glucose monitoring strategies in those who infused and those who did not infuse with teplizumab where possible * To characterize insulin use in those who infused and those who did not infuse with teplizumab where possible * To characterize longitudinal health care resource utilization in those who infused and those who did not infuse with teplizumab

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: Teplizumab — This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Primary Outcomes

  • Change in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions (From baseline, repeated every 6 months up to end of study, approximately 5 years)
  • Change in participant and caregiver-reported outcomes from survey responses: Psychological well-being World Health Organization-5 (WHO-5) (From baseline, repeated every 6 months up to end of study, approximately 5 years)
  • Change in participant and caregiver-reported outcomes from survey responses: State-Trait Anxiety Inventory (STAI) (From baseline, repeated every 6 months up to end of study, approximately 5 years)
  • Change in participant and caregiver-reported outcomes from survey responses: Type 1 Diabetes Distress Assessment System-Core Scale (T1-DDAS CORE) (From baseline, repeated every 6 months, up to end of study, approximately 5 years)
  • Change in participant and caregiver-reported outcomes from survey responses: Diabetes constraints scale (From baseline, repeated every 6 months up to end of study, approximately 5 years)
  • Sociodemographic screening characteristics (At enrollment)
  • Sociodemographic medical history characteristics (At enrollment)
  • Sociodemographic diabetes management characteristics (At enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-31
Completion: 2030-12-03
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 550 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sanofi
Contact Information
Study Contact:
Trial Transparency email recommended (Toll free for US & Canada)
800-633-1610
Contact-US@sanofi.com
PicnicHealth For potential study participants
415-680-3085
hello@picnichealth.com
Interventions
  • Drug: Teplizumab — This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study Locations (1 sites)
Investigational Site, San Francisco, California 94107 United States
Eligibility Criteria
Inclusion Criteria: * History of stage 2 type 1 diabetes with the presence of one or more diabetes-related autoantibodies and dysglycemia confirmed in the medical record * At the time of enrollment either not yet diagnosed with stage 3 type 1 diabetes, or the progression occurred in the last 18 months prior to enrollment * Aged 8 or older at the time of enrollment * Aged 8 or older at the time of teplizumab infusion (if infused) * Receipt of medical care in the United States * Able to and does give written informed consent Exclusion Criteria: \- Failure to complete the baseline survey
Conditions Overweight, Obesity
Phase PHASE3
Enrollment 900
Locations 185 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Eloralintide — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Percent Change from Baseline in Body Weight (Baseline, Week 64)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-10
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
205-870-4343
Birmingham Clinical Research
Interventions
  • Drug: Eloralintide — Administered SC
  • Drug: Placebo — Administered SC
Study Locations (185 sites)
Birmingham Clinical Research, Birmingham, Alabama 35209 United States
RIO Clinical Trials - Phoenix, Phoenix, Arizona 85016 United States
Headlands Research - Scottsdale, Scottsdale, Arizona 85260 United States
Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona 85741 United States
Irvine Clinical Research, Irvine, California 92614 United States
Scripps Whittier Diabetes Institute, La Jolla, California 92037 United States
EndoTrials Center for Clinical Research, La Mesa, California 91942 United States
Peninsula Research Associates, Rolling Hills Estates, California 90274 United States
Care Access - Sacramento, Sacramento, California 95831 United States
Artemis Institute for Clinical Research, San Diego, California 92123 United States
Eligibility Criteria
Inclusion Criteria: * Are on stable incretin therapy at screening * With persistent obesity or overweight defined as: * ≥30 kg/m2 OR * ≥27 kg/m2 with at least one existing obesity related complication at screening: * hypertension * dyslipidemia * obstructive sleep apnea * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or * type 2 diabetes * Have a stable body weight (\<5% body weight change) at screening Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have taken any of the following antihyperglycemic medications within 90 days before screening: * dipeptidyl peptidase-4 (DPP-4) inhibitors * amylin analogs * insulin * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Conditions Diabetes, Diabetic Foot, Diabetes Mellit...
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to create and evaluate and new management, by using eHealth tools, to prevent diabetic foot ulcers. The main questions it aims to answer are: 1. Validation a. Is a method for foot assessment, that uses eHealth tools, valid regarding its usefulness? b. Is a method for foot assessment, that uses eHealth tools, reliable regarding the generated risk stratification? 2. Mapping 1. How do health care professionals and patients with diabetes experience that the future foot examination should be designed? 2. What experiences have health care professionals and patients with diabetes to use an eHealth tool supporting the annual foot examination? 3. Interviews - to use a paper format supporting a structured foot assessment a. How do health care professionals experience to use a structured foot form, in paper form? 4. Interviews - footwear a. What factors that influence how patients with diabetes choose their footwear? 5. Interviews - usability test of using an eHealth tool a. How could a digital eHealth tool be designed? b. How could a digital eHealth solution be implemented, managed and spread in public health care setting? i. Participants will: 1\. fill in questionnaires 2. be interviewed 3. test eHealth solutions supporting the foot examination 6\. Experiences of using an eHealth tool supporting the foot assessment a. How could a digital eHealth tool be designed? 7\. Questionnaires regarding self-perceived quality of life, the experiences of the visit at the care unit, transportation to the care unit. a. Patients that visits care fills in a questionnaire regarding self-perceived quality of life (EQ-5D), a modified version of National Patient Survey, the diabetes questionnaire and a questionnaire regarding their travels and time for travels to and from the visit to the care unit. 8\. Critical evaluation of complexity 1. Exists complexity in the development, test, management, spread and sustain of an eHealth tool supporting foot examination and self-care of the feet in diabetes. 2. How could a digital eHealth solution be implemented, managed and spread in public health care setting? 9\. Long term effect a. What is the long-term effect of using an eHealth tools supporting a structured foot examination?

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Patients being foot examined by using an eHealth tool — Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
  • Other: Patients being foot examined in traditional manner — Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes

Primary Outcomes

  • Validation (2020-2021)
  • Mapping (2020-2023)
  • Interviews - to use a paper format supporting a structured foot assessment (2020-2023)
  • Interviews - footwear (2023-2025)
  • Interviews - usability test of using an eHealth tool (2020-2024)
  • Experiences of using an eHealth tool supporting the foot assessment (2020-2024)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sahlgrenska University Hospital
Collaborators: Vastra Gotaland Region
Contact Information
Study Contact:
Ulla Hellstrand Tang, PhD
0046706397913
ulla.tang@vgregion.se
Ulla Hellstrand Tang, PhD
0046706397913
ulla.tang@vgregion.se
Departmetn of Prosthetics & Orthotics, Sahlgrenska University Hospital
Interventions
  • Other: Patients being foot examined by using an eHealth tool — Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
  • Other: Patients being foot examined in traditional manner — Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
Study Locations (1 sites)
Departmetn of Prosthetics & Orthotics, Sahlgrenska University Hospital, Gothenburg, 41285 Sweden
Eligibility Criteria
Inclusion Criteria patients: * Persons with diabetes being treated in Region Västra Götaland * Understand spoken and written Swedish Exclusion Criteria: • Not understand spoken and written Swedish Inclusion Criteria healthcare professionals: * Professionals working with patients with diabetes having foot complications. * Working in Region Västra Götaland * Understand spoken and written Swedish
Conditions Obesity or Overweight, Type 2 Diabetes M...
Phase PHASE3
Enrollment 1600
Locations 210 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Combination Product: Placebo — Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
  • Combination Product: Enicepatide — Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.

Primary Outcomes

  • Percent (%) Change from Baseline in Body Weight at Week 72 (Baseline through Week 72)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-03-23
Completion: 2028-08-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WC45726 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Combination Product: Placebo — Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
  • Combination Product: Enicepatide — Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.
Study Locations (210 sites)
Lakeview Clinical Research, Guntersville, Alabama 35976 United States
Arizona Clinical Trials, Tucson, Arizona 85711 United States
University of California Irvine, Irvine, California 92612 United States
Orange County Research Center, Lake Forest, California 92630 United States
Ark Clinical Research, Long Beach, California 90815 United States
Catalina Research Institute, LLC, Montclair, California 91763 United States
Infinity Clinical Research, Norco, California 92860 United States
Prospective Research Innovations Inc., Rancho Cucamonga, California 91730 United States
Encompass Clinical Research, Spring Valley, California 91978 United States
Emerson Clinical Research Institute, Washington D.C., District of Columbia 20009 United States
Eligibility Criteria
Inclusion Criteria: * Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations) * Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet/exercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy. * Body mass index (BMI) ≥27.0 kg/m\^2 * History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight Exclusion Criteria: * History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state/coma within 12 months prior to screening * Have had 1 or more episodes of severe hypoglycemia and/or has hypoglycemia unawareness within the 6 months prior to screening * At least 2 confirmed fasting blood glucose values \>270 mg/dL (15.0 mmol/L) (on 2 non-consecutive days) during screening * Self-reported change in body weight \>5 kg within 3 months prior to screening * Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome) * Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed. * Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) * Poorly controlled hypertension at screening * Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure * Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
Conditions Asthma, Pulmonary Function, Wheezing, In...
Phase Not Applicable
Enrollment 225
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The overall aims of this protocol are to determine whether prenatal supplementation with vitamin C to pregnant smokers can improve pulmonary function at 10 years of age in their offspring. This is an additional continuation of the Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) trial, to follow the offspring through 10 years of age. The hypothesis for this protocol is an extension of the VCSIP trial that supplemental vitamin C in pregnant smokers can significantly improve their children's airway function tests. The investigators aim to demonstrate sustained improvement in airway/pulmonary function and trajectory through 10 years of age.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Dietary Supplement: No active intervention in this protocol (previously randomized to Vitamin C) — In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
  • Other: No active intervention in this protocol (previously randomized to Placebo) — In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.

Primary Outcomes

  • Sustained improvement in pulmonary function and trajectory (10 years of age)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-11
Completion: 2028-08
Eligibility
Age: 6 Years – 16 Years
Sex: ALL
Volunteers: false
Enrollment: 225 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon Health and Science University
Collaborators: Indiana University, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Cindy McEvoy, MD, MCR (PRINCIPAL_INVESTIGATOR) - Oregon Health and Science University
Contact Information
Study Contact:
Cindy McEvoy, MD, MCR
503-494-0223
mcevoyc@ohsu.edu
Kristin Milner, BS, CMA, CCRP
503-494-0223
milner@ohsu.edu
Christina Tiller
ctiller@iu.edu
Indiana University
Interventions
  • Dietary Supplement: No active intervention in this protocol (previously randomized to Vitamin C) — In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
  • Other: No active intervention in this protocol (previously randomized to Placebo) — In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
Study Locations (2 sites)
Indiana University, Indianapolis, Indiana 46902 United States
Oregon Health and Science University (OHSU), Portland, Oregon 97217 United States
Eligibility Criteria
Inclusion Criteria: * Women and their offspring randomized to vitamin C versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original VCSIP study Exclusion Criteria: * participants who specifically withdraw consent
Conditions Asthma (Diagnosis)
Phase NA
Enrollment 160
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Asthma affects nearly 1 in 10 teenagers in the United States and can seriously impact their health and daily life. Teens are expected to manage their asthma by taking medications correctly and paying attention to symptoms, but this can be hard. Adolescents are still developing the skills needed to manage their thoughts, feelings, and behaviors, and they often receive less help from parents during this time. Because each teen struggles in different ways and at different times, they need support that is personalized and responds to what is happening in the moment. Smartphones offer a promising way to help teens manage asthma well. However, most existing asthma apps do not use the full range of proven behavior-change strategies or adapt to what the teen is actually doing day to day. To address this gap, our team created Responsive Asthma Care for Teens (ReACT)-a system that collects data about each time an adolescent takes or misses a dose of medication and monitors symptoms. ReACT helps teens set goals, get feedback, notice barriers, and practice problem-solving skills. Early testing showed that teens liked ReACT and that it improved the skills needed for better asthma management. In this study, the investigators will pilot test ReACT in a study with 160 teens ages 13-17 who have poorly controlled asthma. Teens will be randomly assigned to use ReACT or a comparison intervention for six months. The comparison intervention provides basic asthma education and a place to log symptoms and medication use-similar to what they might normally receive in standard care. Investigators will look at how well the study procedures work across multiple sites and whether ReACT improves the skills that help teens manage their asthma. The investigators will also explore whether ReACT leads to better asthma control and quality of life. Teens will complete assessments at the start of the study, at three months, and at six months. The investigators will gather information through surveys and objective data such as medication use. By the end of this project, the investigators will know whether the ReACT system and study protocol are feasible and ready for a larger clinical trial, and will have early estimates of how much ReACT may improve asthma outcomes for teens.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Sensor-Enabled mHealth Intervention for Adolescents with Suboptimal Asthma Control — Participants assigned to ReACT will contribute passively monitored sensor data to track their adherence to their asthma regimen. They will also report on their symptoms. These data will be used to provide tailored feedback and support delivered via text message. These messages will encourage adolescents to adhere to their asthma regimen and address barriers using problem-solving skills taught to them at baseline.
  • Behavioral: mHealth standard of care control condition — Participants assigned to ReACT will contribute passively monitored sensor data to track their adherence to their asthma regimen. They will also report on their symptoms. Participants will be provided with general asthma education at baseline.

Primary Outcomes

  • Feasibility of Recruitment (6 months)
  • Retention (6 months)
  • Engagement (6 months)
  • Acceptability (6 months)
  • Usability (The System Usabiltity Scale is a 10-item measure scored on a 5-point Likert scale. It assesses ease of use, learnability, user conficence, system complexity, and need for technical support.)
  • Burden (6 months)
  • Qualitative Acceptability (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-22
Completion: 2028-01-15
Eligibility
Age: 13 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Kansas
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Christopher C. Cushing, Ph.D.
785-864-0713
christopher.cushing@ku.edu
David A. Fedele, Ph.D., ABPP
904-697-2610
david.fedele@nemours.org
Nemours Children's Health
Christopher C Cushing, Ph.D.
785-864-0713
christopher.cushing@ku.edu
University of Kanas
Interventions
  • Behavioral: Sensor-Enabled mHealth Intervention for Adolescents with Suboptimal Asthma Control — Participants assigned to ReACT will contribute passively monitored sensor data to track their adherence to their asthma regimen. They will also report on their symptoms. These data will be used to provide tailored feedback and support delivered via text message. These messages will encourage adolescents to adhere to their asthma regimen and address barriers using problem-solving skills taught to them at baseline.
  • Behavioral: mHealth standard of care control condition — Participants assigned to ReACT will contribute passively monitored sensor data to track their adherence to their asthma regimen. They will also report on their symptoms. Participants will be provided with general asthma education at baseline.
Study Locations (2 sites)
Nemours Children's Health, Jacksonville, Florida 32207 United States
University of Kanas, Lawrence, Kansas 66045 United States
Eligibility Criteria
Inclusion criteria for adolescents are: 1) they are between 13-17 years-old; 2) they have a physician-verified diagnosis of persistent asthma for at least 6 months; 3) they have suboptimal asthma control as defined by national asthma guidelines;5 4) they have a daily inhaled corticosteroid prescription that is compatible with the ReACT sensor; and 5) the adolescent-caregiver dyad speak and read English. Exclusion criteria are: 1) the adolescent is currently involved in an asthma management intervention beyond usual care; 2) the adolescent has a comorbid chronic health condition that may impact lung function (e.g., cystic fibrosis); 3) the adolescent has significant cognitive impairment or developmental delay that interferes with study completion, and 4) the adolescent does not have their own smart phone. Consistent with national asthma guidelines, we define suboptimal as control as a score of ≤19 on the Asthma Control Test (ACT) or by endorsing one or more of the following symptoms of on \>4 days in the past 2 weeks: (a) use of any short-acting beta-agonist medication, (b) experiencing asthma symptoms (i.e., wheezing, tightness of chest, coughing) during the day or night, (c) nighttime awakening due to asthma, or (d) activity limitation or school absence due to asthma.
Conditions Asthma
Phase Not Applicable
Enrollment 2500
Locations 71 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Procedure: Investigational Procedures — Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.
  • Other: Procedure: Investigational Procedures — Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Primary Outcomes

  • Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities (Part 1: At baseline)
  • Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma (Part 1: At baseline)
  • Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma (Part 1: At baseline)
  • Part 1: Physician Global Assessment of Asthma Severity and Symptom Control (Part 1: At baseline)
  • Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2 (Part 2: At Weeks 52 and 104)
  • Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2 (Part 2: At Weeks 52 and 104)
  • Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2 (Part-2: At Weeks 52 and 104)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-01
Completion: 2029-04-04
Eligibility
Age: 6 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sanofi
Collaborators: Syneos Health
Contact Information
Study Contact:
Trial Transparency email recommended-Toll free for US & Canada
800-633-1610
Contact-US@sanofi.com
Interventions
  • Other: Procedure: Investigational Procedures — Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.
  • Other: Procedure: Investigational Procedures — Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.
Study Locations (71 sites)
Trinity Clinical Research, LLC - Bessemer - Site Number: 840150, Bessemer, Alabama 35022 United States
Chandler Clinical Trials - Site Number: 840106, Chandler, Arizona 85224 United States
Del Sol Research Management, LLC - Mesa - Site Number: 840123, Mesa, Arizona 85206 United States
Orso Health - Scottsdale - Site Number: 840133, Scottsdale, Arizona 85254 United States
Sun City Clinical Trials - Elite - Site Number: 840120, Sun City, Arizona 85351 United States
FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158, California City, California 91107 United States
Imax Clinical Trials - Site Number: 840109, La Palma, California 90623 United States
Downtown LA Research - Site Number: 840161, Los Angeles, California 90017 United States
Newport Native MD, Inc. - Site Number: 840101, Newport Beach, California 92663 United States
Pasadena Clinical Trials - Site Number: 840116, Pasadena, California 91101 United States
Eligibility Criteria
Inclusion Criteria: Applicable for Part 1 participants: * Age 6 years and older, at the time of signing the informed consent * Physician diagnosis of asthma for at least 12 months * Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps * Participant or legally authorized representative (where applicable) has consented to participate Applicable for Part 2 participants: * Age 18 years and older, at the time of signing the informed consent. * Physician diagnosis of asthma for at least 12 months * Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps * Participant or legally authorized representative (where applicable) has consented to participate * Participants must meet the criteria for at least one of the cohorts below: A) Asthma control cohorts 1. ACQ-5 \>= 1.5 2. ACQ-5 \< 1.5 (B) Type-2 biomarker cohorts 3. Elevated T2 biomarkers (B1: Type-2-high cohort) 4. Low T2 biomarkers (B2: Type-2-low cohort) Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants): * Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure * Participants with moderate/severe cognitive impairment. * Participants with moderate/severe cardiac disease. * Participants on immunosuppressive medication for a chronic condition. * Participation in other interventional and noninterventional clinical study (currently or in the past 3 months) The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Conditions Healthy Volunteer Study, Healthy Adults,...
Phase PHASE1
Enrollment 133
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeking participants who: * Are healthy (do not have disease) males or females who can no longer have children, * Are 18 to 65 years old, * Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight For Part A (optional group or cohort 3: Japanese participants only): * A body weight of more than 45 kilograms (100 pounds). * Have 4 biological Japanese grandparents who were born in Japan. For Part E only: * Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study. * Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). The study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand: * how the body processes the study medicine in healthy participants (Parts A and B), * how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C), * how the study medicine is broken down and leaves the body in healthy participants (Optional Part D), * how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E), * if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F). Participants will take part in the study for about 10 weeks (Parts A and F), 12 weeks (Part B), 9 weeks (Parts C and D), and 16 weeks (Part E). During this time, they will have 2 study visits at the study clinic and up to 28 overnight stays (Part A), 18 overnight stays (Parts B and E), 10 overnight stays (Part C), 11 overnight stays (Part D), and 16 overnight stays (Part F). The study team will also call participants 1 time over the phone at the end of the study to assess how they are doing. Study measurements will be taken by body examination, monitoring side effects, blood and urine tests, heart tests (ECG), vital signs (blood pressure, pulse and respiratory rate), questionnaires (Parts C and E), stool samples (Part D only), and breathing tests (Part E only).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: PF-08103402 — Oral suspension (Parts A to F); Tablets (Parts C and F only)
  • Drug: Placebo — Oral suspension (Parts A, B and E).
  • Drug: Midazolam — Oral syrup

Primary Outcomes

  • Number of Participants with Treatment Emergent Adverse Events (TEAEs) (Parts A: Up to Day 36; Part B and E: Up to Day 50)
  • Number of Participants with Serious Adverse Events (SAEs) (Parts A: Up to Day 36; Part B and E: Up to Day 50)
  • Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities (Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17)
  • Number of Participants With Clinically Significant Change From Baseline in Vital Signs (Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17)
  • Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings (Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17)
  • Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise (AUClast) in the fasted state (Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1)
  • Maximum observed plasma concentration (Cmax) in the fasted state (Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1)
  • Total recovery of drug-related material in urine and feces separately, and both routes combined, expressed as a percent of total dose administered (Pre-dose (Hour 0) and at 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-17
Completion: 2027-03-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 133 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: PF-08103402 — Oral suspension (Parts A to F); Tablets (Parts C and F only)
  • Drug: Placebo — Oral suspension (Parts A, B and E).
  • Drug: Midazolam — Oral syrup
Study Locations (1 sites)
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut 06511 United States
Eligibility Criteria
Key Inclusion criteria (Parts A, B, C, D and F): 1. Are males or females who can no longer have children, 2. Are 18 to 65 years old, 3. Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). For Part A (Optional group or cohort 3: Japanese participants only): 1. A total body weight of more than 45 kg (100 pounds). 2. Have 4 biological Japanese grandparents who were born in Japan. For Part E only: 1. Adults with a documented doctor's-diagnosis history of asthma for at least 12 months before entering the study. 2. Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). Key Exclusion criteria 1. Evidence or history of clinically significant medical conditions. 2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb). 3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. 4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. 5. Any history of parasitic infection requiring treatment within 28 days prior to screening. 6. Positive tuberculosis infection test result. 7. Part C only: Evidence or history of conditions interfering with the ability to taste. 8. Part D only: History of irregular bowel movements. 9. Part E only: Evidence of lung disease(s) other than asthma. 10. Part E only: Asthma exacerbation within 3 months prior to screening. 11. Part F only: History of acute narrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, respiratory insufficiency, myasthenia gravis or adverse reaction to midazolam or other benzodiazepines.

Diaphragmatic Function as a Biomarker

NCT05903001
Recruiting
Conditions Dyspnea; Asthmatic, COPD, Fibrosis, Pulm...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Diaphragm Ultrasound — Ultrasound of the Diaphragm at the end of inspiration and expiration
  • Diagnostic Test: Intercostal Muscle Ultrasound — Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
  • Diagnostic Test: Borg scale — Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
  • Diagnostic Test: MRC Breathlessness Scale — The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
  • Diagnostic Test: Respiratory Questionaire — Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
  • Diagnostic Test: GINA classification of Asthma — Patients are classified according to the GINA classification of Asthma.
  • Diagnostic Test: Measurement of respiratory mouth pressure — Inspiratory and expiratory Measurement of respiratory mouth pressure
  • Diagnostic Test: SNIP — Measurement of Sniff Nasal Inspiratory Pressure

Primary Outcomes

  • Dyspnea Borg scale 1 to 10 (6 months recruiting)
  • Dyspnea Borg scale 1 to 10 (follow up 3 months after recruitment)
  • Dyspnea Borg scale 1 to 10 (follow up 6 months after recruitment)
  • Dyspnea Borg scale 1 to 10 (follow up 12 months after recruitment)
  • Dyspnea Borg scale 1 to 10 (follow up 18 months after recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-01
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RWTH Aachen University
Principal Investigators:
  • Michael Dreher, MD (STUDY_DIRECTOR) - Uniklinik RWTH Aachen
  • Binaya Regmi, MD (STUDY_CHAIR) - Uniklinik RWTH Aachen
  • Jens Spiesshoefer, MD (PRINCIPAL_INVESTIGATOR) - Uniklinik RWTH Aachen
Contact Information
Study Contact:
Jens Spiesshoefer, MD
0049 2418037036
jspiesshoefer@ukaachen.de
Jens Spiesshoefer, PhD
+492418037036
jspiesshoefer@ukaachen.de
RWTH Aachen University Hospital
Binaya Regmi, MD
+492418037065
bregmi@ukaachen.de
RWTH Aachen University Hospital
Interventions
  • Diagnostic Test: Diaphragm Ultrasound — Ultrasound of the Diaphragm at the end of inspiration and expiration
  • Diagnostic Test: Intercostal Muscle Ultrasound — Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
  • Diagnostic Test: Borg scale — Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
  • Diagnostic Test: MRC Breathlessness Scale — The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
  • Diagnostic Test: Respiratory Questionaire — Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
Study Locations (1 sites)
RWTH Aachen University Hospital, Aachen, North Rhine-Westphalia 52074 Germany
Eligibility Criteria
Inclusion Criteria: * patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension * is 18 years or older * is mentally and physically able to understand the study and to follow instructions * are legally competent * signed declaration of consent Exclusion Criteria: * BMI \> 35 * current or treatments or diseases in the past which could influence the evaluation of the study * Expected lack of willingness to actively participate in study-related measures * alcohol or drug abuse * disc herniation/prolapse * epilepsy * wheelchair bound * in custody due to an official or court order * in a dependent relationship or employment relationship with investigating physician or one of their deputy * emergency inpatient hospital stay within 4 weeks before study-specific examinations

Swiss Severe Asthma Register

NCT03984253
Recruiting
Conditions Severe Asthma
Phase Not Applicable
Enrollment 600
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction. The variability of airway obstruction is triggered by different factors that lead to a variety of different asthma phenotypes and subtypes. The various classification options for asthma (e.g. severity, by the predominantly existing inflammation or according to triggers), reflect its heterogeneity. Despite improved therapeutic methods, the prevalence and morbidity of asthma has increased worldwide in the last years. Asthma is a serious and growing global health problem with around 300 million people affected, independent of age or sex. Estimated 250'000 people die prematurely each year due to their asthma. Based on the SAPALDIA-study, the prevalence of Asthma in Switzerland is approximately 2-8%. Asthma is considered as a major factor in healthcare cost with up to CHF 1.2 billion per year. Asthma is not only a financial burden to a system; it affects the individual Quality of life negatively. Often health care professionals and patients underestimate the severity of the disease and overestimate asthma control. Severe asthma should not be equated with uncontrolled asthma. To reach a satisfying asthma control numerous factors need to be taken into consideration. Severe asthma is often associated with a high risk of frequent, severe exacerbations, which can even lead to death. Several severe asthma cohorts and registries already exists and are reported in the literature. The aim of such registries is in general data collection and a better understanding of the disease. So far, most epidemiological studies on severe asthma are cross-sectional with no follow up measures. Only a few studies did repeated measures using the same methods. Approximately 5% of all Asthma Patients suffers from severe asthma. These patients require systematic assessment and specialist care in dedicated respiratory centres. These centres have a key role in improving the outcome for severe asthma patients. At the same time they act as gatekeepers to ensure appropriate access to new, expensive therapies, this includes antibody treatment and interventional methods such as thermoplasty. These treatments require careful monitoring. It is important to ensure that they are given to the right population. Special assessment to monitor the efficacy and to prevent inappropriate prescribing, exposure of patients to unnecessary risks and excessive costs is indicated. For all the mentioned reasons a Swiss Severe Asthma Register and a collaboration with an already existing register is needed to prospectively collect data about severe asthma in Switzerland.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Symptom Control (Baseline, four months, yearly for up to 15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-05-13
Completion: 2034-02-28
Eligibility
Age: 1 Year and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Dr. Jörg Leuppi
Collaborators: AstraZeneca, GlaxoSmithKline, Lungenliga Schweiz, Novartis
Principal Investigators:
  • Jörg Leuppi (PRINCIPAL_INVESTIGATOR) - Kantonsspital Baselland Liestal
Contact Information
Study Contact:
Jörg Leuppi
+41619252181
Joerg.leuppi@ksbl.ch
Jörg Leuppi, Professor
joerg.leuppi@ksbl.ch
Cantonal Hospital Baselland Liestal
Nikolay Pavlov, MD
nikolay.pavlov@insel.ch
Universitätsklinik für Pneumologie, Inselspital
Interventions
N/A
Study Locations (10 sites)
Cantonal Hospital Baselland Liestal, Liestal, Basel-Landschaft 4410 Switzerland
Universitätsklinik für Pneumologie, Inselspital, Bern, Switzerland
Pneumologie, Kantonsspital Graubünden, Chur, Switzerland
Klinik für Pneumologie, Hochgebirgsklinik Davos, Davos, Switzerland
Hôpitaux Universitaires Genève, Geneva, Switzerland
Centre hospitalier universitaire vaudoise, Lausanne, Switzerland
Pneumologia, Ospedale Civico, Lugano, Switzerland
Klinik für Pneumologie und Schlafmedizin, Kantonsspital St.Gallen, Sankt Gallen, Switzerland
Hôpital du valais, sion, Sion, Switzerland
Klinik für Pneumologie, Universitätsspital Zürich, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: * In- and outpatients * Age ≥ 0 year * Informed consent as documented by signature Adults: "Asthma which requires treatment with guidelines suggested medications for GINA steps 4-5 asthma: * High level therapy: 1. high dose ICS with ≥ 1000 μg beclomethasone (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year or 2. Daily long-term therapy with systemic corticosteroids (CS) for ≥50% of the previous year to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy or 3. Therapy with monoclonal antibodies independent from the co-therapy * Middle level therapy: Protokollsynopsis SAR Version 01 16.01.2019 Seite 4/10 a) Daily long-term therapy with medium-to high-dose ICS (≥500 μg Beclomethason (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year and uncontrolled asthma defined as at least one of the following: * Poor symptom control: ACQ consistently \>1.5, ACT \<20 (or "not well controlled" by NAEPP/GINA guidelines). * Frequent severe exacerbations: two or more bursts of systemic CS (\>3 days each) in the previous year. * Serious exacerbations: at least one hospitalization, ICU stay or mechanical ventilation in the previous year. * Airflow limitation: after appropriate bronchodilator withhold FEV1 \<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal). * Controlled asthma that worsens on tapering of these high doses of ICS or systemic CS (or additional biologics). The presence of any one of the following exclusion criteria will lead to exclusion of the patients: * Life-expectancy \<6 months * Insufficient knowledge of project language Children: The criteria for severe or difficult asthma in children and adolescents are considered fulfilled in the case of insufficient symptom control in the last year despite medium/high antiinflammatory long-term therapy: * age 0-18 years, at time of inclusion * diagnosis of bronchial asthma made by a physician * differential diagnoses excluded * good compliance and trained inhalation technique * treatment with biological approved for the treatment of severe asthma (currently only omalizumab) or Proof of: a) Positive Bronchodilation-test (≥12% increase in FEV1 after SABA) or b) Significant bronchial hyperresponsiveness after nonspecific provocation (e.g., with Methacholine or treadmill) according to ATS criteria (AJRCCM 2000) * High level of therapy: 1. Prolonged therapy with high dose inhaled steroid (ICS) (\> 400 μg Budesonide equivalent /\> 200 μg fluticasone alone); or 2. Daily long-term therapy with medium- to high-dose ICS (≥ 400 μg Budesonide equivalent / ≥200 μg fluticasone) in combination with long-acting betaagonists and / or leukotriene receptor antagonist and / or theophylline; or 3. Therapy with oral steroids fixed ≥3 last months. * Insufficient asthma control a) Inadequate symptom control after NVL in the last 4 weeks: Protokollsynopsis SAR Version 01 16.01.2019 Seite 5/10 * ≥3 x weekly asthma symptoms or use of ondemand medication; Or: * limited activity due to asthma; Or: * any symptoms at night; or b. Exacerbation(s) ≥1 last year that required treatment with systemic steroids and / or inpatient treatment c. limited lung function: * pathological Tiffeneau quotient or FEV1 at inclusion. * Submission of a written consent (parent/ legal guardian). Exclusion Criteria: * Life-expectancy \<6 months · Insufficient knowledge of project language
Conditions Asthma
Phase PHASE3
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The aim EXACT@Home is to create an evidence-based health program using e.g. questionnaires, a digital health platform and multiple digital devices to further improve the assessment of patients diagnosed with severe asthma. By better charting treatable traits (e.g. poor adherence, physical inactivity, dysfunctional breathing), we expect to improve the indication for the use of biologics. One the devices that will be used is also a medicinal product: a digital inhaler, which monitors adherence and inhaler technique through its connected application and aims to improve adherence and inhaler technique with reminders and notifications. Next to this an activity tracker, hand-held spirometer and FeNO measuring device will be used. The information of the devices will be collected in a Personal Digital Healthcare Environment (PDHE). Patients diagnosed with severe asthma according to the regional asthma Multi-Disciplinary Team Meeting (MDTM) eligible for a treatment with biologics will be included. Half of the patients will immediately receive a biologic. The other half will first undergo the systematic assessment including home monitoring (=EXACT@home) and afterwards a treatment will be chosen based on this evaluation: optimization of treatable traits when present and/or biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Budesonide/Formoterol fumarate dihydrate — The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months. It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.

Primary Outcomes

  • Difference in percentage of patients treated with biologicals after 6 months of follow up (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-01-31
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Franciscus Gasthuis
Collaborators: Teva Pharmaceuticals USA
Principal Investigators:
  • J.C.C.M. In &amp;amp;#39;t Veen, dr. (PRINCIPAL_INVESTIGATOR) - Franciscus Gasthuis &amp;amp;amp; Vlietland
Contact Information
Study Contact:
L. Bult, drs.
+31104616149
l.bult@franciscus.nl
J.C.C.M. In &amp;#39;t Veen, dr.
h.intveen@franciscus.nl
L. Bult
+31104616149
l.bult@franciscus.nl
Franciscus Gasthuis &amp; Vlietland
Interventions
  • Drug: Budesonide/Formoterol fumarate dihydrate — The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months. It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Study Locations (1 sites)
Franciscus Gasthuis &amp; Vlietland, Rotterdam, South Holland 3045PM Netherlands
Eligibility Criteria
Inclusion criteria: * Confirmed asthma diagnoses (≥12% and \>200 ml reversibility in FEV1 or positive histamine/methacholine provocation test or FeNO ≥50) according to the asthma guidelines * Diagnosed with severe, refractory asthma with eligibility for treatment with specific asthma biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab) as determined at the regional asthma MDTM according to the asthma guidelines * Age ≥ 18 years. * Previous prescribed asthma biologics have to be ceased ≥ 4 times the half-life of that specific biologic. * The patient has be relatively stable. The onset of an asthma exacerbation and/or a respiratory infection has to be ≥ 4 weeks ago. Exclusion criteria: * Primary COPD diagnosis. * History of cancer: * Current basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to the start of the study. * Current other malignancies. Patients are eligible to participate in the study provided that curative therapy was completed at least 5 years prior to the start of the study. * Inability to sufficiently understand and read the Dutch language. * Being unable to engage in a remote monitoring and coaching program through the use of a smartphone. * Being unable to engage in physical activity (e.g. physical disability). * Current pregnancy. * Current breastfeeding. * A liaison with the coordinating or (principal) investigator, which could likely influence the decision to participate in this study voluntarily (in concordance with the WMO - article 5).